Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing

Analytical Cellular Pathology

Volumn 34, Issue 1-2, 2011, Pages 61-66

  Richman, Susan D ^a   Chambers, Philip ^a   Seymour, Matthew T ^a   Daly, Catherine ^a   Grant, Sophie ^a   Hemmings, Gemma ^a   Quirke, Philip ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

BRAF; colorectal cancer; heterogeneity; KRAS

Indexed keywords

B RAF KINASE; DNA; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN;

ADVANCED CANCER; ARTICLE; CODON; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DNA EXTRACTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PYROSEQUENCING; WILD TYPE;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS;

EID: 79960798099     PISSN: 22107177     EISSN: 22107185     Source Type: Journal    
DOI: 10.3233/ACP-2011-0005     Document Type: Article

References (18)

1. A. de Gramont, A. Figer,M. Seymour,M. Homerin, A. Hmissi and J. Cassidy, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol 18(16) (2000), 2938-2947. (Pubitemid 30644117)
2. J.Y. Douillard, D. Cunningham, A.D. Roth, M. Navarro, R.D. James and P. Karasek, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet 355(9209) (2000), 1041-1047. (Pubitemid 30162806)
3. L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen, L. Fehrenbacher and M.J. Moore, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med 343(13) (2000), 905-914.
4. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth and W. Heim, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med 350(23) (2004), 2335-2342. (Pubitemid 38702844)
5. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg and A. Santoro, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med 351(4) (2004), 337-345. (Pubitemid 38944402)
6. P. Tappenden, R. Jones, S. Paisley and C. Carroll, Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer, Health Technol Assess 11(12) (2007), 1-128, iii-iv.
7. R.A. Adams, A.M. Meade, A. Madi, D. Fisher, E. Kay and S.Kenny, Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience, Br J Cancer 100(2) (2009), 251-258.
8. J.R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad and D. Spigel, A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer, J Clin Oncol 27(5) (2009), 672-680.
9. J. Tol, M. Koopman, A. Cats, C.J. Rodenburg, G.J. Creemers, J.G. Schrama and F.L. Erdkamp, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N Engl J Med 360(6) (2009), 563-572.
10. S. Bamford, E. Dawson, S. Forbes, J. Clements, R. Pettett and A. Dogan, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br J Cancer 91(2) (2004), 355-358. (Pubitemid 39037083)
11. J.L. Bos, E.R. Fearon, S.R. Hamilton, M.Verlaan-de Vries, J.H. van Boom and A.J. van der Eb, Prevalence of ras gene mutations in human colorectal cancers, Nature 327(6120) (1987), 293-297. (Pubitemid 17075079)
12. S.D. Finkelstein, R. Sayegh, S. Christensen and P.A. Swalsky, Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type, Cancer 71(12) (1993), 3827-3838. (Pubitemid 23172957)
13. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore- Bianchi, S. Arena and P. Saletti, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, J Clin Oncol 26(35) (2008), 5705-5712.
14. S.D. Richman, M.T. Seymour, P. Chambers, F. Elliott, C. Daly and A.M. Meade, KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS Trial, J Clin Oncol 27(35) (2009), 5931-5937.
15. J. Tol, I.D. Nagtegaal and C.J. Punt, BRAF mutation in metastatic colorectal cancer, N Engl J Med 361(1) (2009), 98-99.
16. J.H. van Krieken, A. Jung, T. Kirchner, F. Carneiro, R. Seruca and F. Bosman, KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program, Virchows Arch 453(5) (2008), 417-431.
17. M.T. Seymour, T.S. Maughan, J.A. Ledermann, C. Topham, R. James and S.J. Gwyther, Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial, Lancet 370(9582) (2007), 143-152. (Pubitemid 47042894)
18. S. Edkins, S. O'Meara, A. Parker, C. Stevens, M. Reis and S. Jones, Recurrent KRAS codon 146 mutations in human colorectal cancer, Cancer Biol Ther 5(8) (2006), 928-932.